UBS AM’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$852 Sell
298
-3,856
-93% -$11.8K ﹤0.01% 4145
2026
Q2
$12.6K Hold
4,154
– – ﹤0.01% 3222
2026
Q1
$12.8K Buy
4,154
+3,482
+518% +$14.8K ﹤0.01% 3247
2025
Q4
$2.43K Buy
+672
New +$2.93K ﹤0.01% 3104
2025
Q3
– Sell
-4,215
Closed -$16.3K – 2284
2025
Q2
$16.3K Sell
4,215
-102,657
-96% -$556K ﹤0.01% 2612
2025
Q1
$534K Buy
106,872
+14,480
+16% +$91.7K ﹤0.01% 2487
2024
Q4
$666K Buy
92,392
+13,126
+17% +$100K ﹤0.01% 2502
2024
Q3
$487K Sell
79,266
-25,916
-25% -$176K ﹤0.01% 2651
2024
Q2
$699K Buy
105,182
+86,982
+478% +$642K ﹤0.01% 2531
2024
Q1
$185K Buy
+18,200
New +$185K ﹤0.01% 2471
2023
Q3
– Sell
-19,200
Closed -$81K – 2590
2023
Q2
$81K Hold
19,200
– – ﹤0.01% 2651
2023
Q1
$81K Sell
19,200
-35,500
-65% -$422K ﹤0.01% 2651
2022
Q4
$900K Buy
+54,700
New +$614K ﹤0.01% 1900

Other funds holding ALT

UBS AM's ALT Position: Q3 2026 in Review

UBS AM reduced its Altimmune (ALT) stake by 93% in Q3 2026, selling an estimated $11.8K and leaving 298 shares worth $852. The position accounts for ﹤0.01% of the portfolio, ranked #4145.

UBS AM first reported a position in ALT in Q4 2022 and has held it in 13 quarters since. The position peaked at $900K in Q4 2022. 155 funds tracked by Wall St. Rank hold ALT as of Q3 2026.

  • UBS AM held 298 shares of Altimmune worth $852 as of Q3 2026.
  • UBS AM sold 3,856 Altimmune shares in Q3 2026, an estimated $11.8K.
  • Altimmune made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4145 holding.
  • UBS AM first reported a position in Altimmune in Q4 2022 and has held it in 13 quarters since.
  • UBS AM's Altimmune position peaked at $900K in Q4 2022.
  • 155 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.